Sandostatin · DIN 00839191 · 50 mcg/mL · injection solution - 1mL Amp Pk
General benefitDormant since June 18, 2025 · checked November 17, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Sandostatin · DIN 00839191
Manufacturer: Novartis Pharma Canada Inc.; listing date 2007-01-02
Health Canada: Dormant since 2025-06-18 · brand SANDOSTATIN · ATC H01CB02 OCTREOTIDE · form Solution · route Subcutaneous, Intravenous · ingredients OCTREOTIDE (OCTREOTIDE ACETATE) 50 MCG/ML · company Novartis pharmaceuticals canada inc · schedule Prescription
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed April 15, 1998; live record preferred: Dormant June 18, 2025 (checked November 17, 2026) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00839191)
Source record
DIN 00839191: Sandostatin
Raw flags: sec3=Y
Item: 920000083; group id 942; item number 2245; lccId None; manufacturer id NOV
Source form: Inj Sol - 1mL Amp Pk; strength: 50mcg/mL
Recorded listing: General benefit
Source prices (unrounded): $5.3440; ministry $4.0080
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00839191
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada); extract: Marketed April 15, 1998; live record preferred: Dormant June 18, 2025 (checked November 17, 2026) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9915
Interchangeable products
Octreotide Acetate Omega · DIN 02248639 · $4.0080
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since June 18, 2025 — choose a marketed DIN from the same-category list.